Amorphous calcium carbonate for treating a leukemia

Abstract

The present invention provides compositions and methods of treating a leukemia, including chronic lymphocytic leukemia, wherein the method comprises administering a stabilized amorphous calcium carbonate to a person in need thereof.

1 . A method of treating a leukemia in a subject in need thereof, the method comprising:
 administering a composition including an effective amount of amorphous calcium carbonate (ACC) stabilized by at least one stabilizing agent.   
     
     
         2 . The method of  claim 1 , wherein the leukemia is a chronic leukemia selected from the group consisting of chronic lymphocytic leukemia, chronic myelogenous leukemia, and Hairy cell leukemia, or an acute leukemia selected from the group consisting of acute myeloid leukemia and acute lymphoblastic leukemia. 
     
     
         3 . The method of  claim 2 , wherein the leukemia is a chronic lymphocytic leukemia. 
     
     
         4 . The method of  claim 1 , wherein the at least one stabilizing agent is selected from the group consisting of polyphosphate, organic acid, phosphorylated amino acids, bisphosphonate, phosphorylated organic acid, phosphoric or sulfuric ester of hydroxy carboxylic acid, hydroxyl bearing organic compound combined with alkali hydroxides and any combination thereof. 
     
     
         5 . The method of  claim 4 , wherein the polyphosphate is an inorganic polyphosphate selected from the group consisting of triphosphate, pyrophosphate. and hexametaphosphate; the phosphorylated amino acid is selected from the group consisting of phosphoserine or phosphothreonine; the organic acid is selected from the group consisting of citric acid and tartaric acid; and the bisphosphonate is selected from the group consisting of alendronate, etidronic acid, zoledronic acid, and medronic acid. 
     
     
         6 . The method of  claim 5 , wherein the at least one stabilizing agent is a polyphosphate or bisphosphonate, and wherein the molar ratio between P atoms of the stabilizing agent and Ca atoms of the ACC is about 1:90 to 1:1. 
     
     
         7 . The method of  claim 1 , wherein treating a leukemia includes at least one of ceasing, retarding, reversing, or preventing the development of the leukemia. 
     
     
         8 . The method of  claim 7 , wherein ceasing, retarding, reversing, or preventing the development of the leukemia includes ceasing, retarding, or reversing the progression of lymphocytosis. 
     
     
         9 . The method of  claim 8 , wherein ceasing the progression of lymphocytosis includes preserving the level of white blood cells at the same level for at least 3 months. 
     
     
         10 . The method of  claim 1 , further comprising administering about 500 mg/day to about 5000 mg/day of ACC. 
     
     
         11 . The method of  claim 1 , wherein the composition is formulated as a pharmaceutical composition or nutraceutical composition, a food supplement, or a medical food.